NovaBridge Biosciences ADR Dossier - Source-backed chat

NovaBridge Biosciences ADR

NBPNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.31

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.34Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $155M

Enterprise Value −$52.6M

Shares Outstanding 220.3M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

NovaBridge Biosciences (formerly I-Mab) has successfully transitioned from a China-focused biotech to a global hub-and-spoke platform. Backed by the CBC Group, the company is well-capitalized with $210.8 million in cash (as of Dec 31, 2025), providing a runway through 2028. Its lead asset, Givastomig (a CLDN18.2 x 4-1BB bispecific antibody), recently received FDA Fast Track Designation and has demonstrated a compelling 75%-77% ORR and 16.9-month mPFS in Phase 1b. With a registrational Phase 3 trial expected to begin in late 2026 and a second high-potential asset, VIS-101, entering Phase 2b in H2 2026, NovaBridge offers an asymmetric risk-reward profile at its current valuation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$7.00

Mean target$8.00

High · most bullish analyst$9.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.5020%

Givastomig's Phase 3 trial faces regulatory or enrollment delays, pushing initiation into mid-2027. VIS-101's Phase 2b trial shows safety signals or fails to replicate the durability seen in Phase 2a. High R&D cash burn accelerates, shortening the cash runway to late 2027 and forcing dilutive equity financing. The HKEX dual listing is delayed or cancelled due to unfavorable market conditions.

Base CaseCentral scenario

$8.0050%

Matches the consensus mean

Givastomig successfully enters Phase 3 in late 2026 / early 2027, and detailed Phase 1b data presented in H2 2026 remains highly competitive. VIS-101 advances into Phase 2b in H2 2026 as planned. The company's cash runway remains sufficient to fund operations through 2028, and the HKEX dual listing progresses steadily. Valuation aligns with consensus analyst targets as clinical milestones are met.

Bull CaseUpside scenario

$9.0030%

Givastomig's Phase 3 trial initiates ahead of schedule in Q4 2026 and demonstrates superior efficacy and safety compared to standard of care, leading to accelerated FDA approval. VIS-101's Phase 2b data confirms best-in-class durability in wet AMD, prompting a lucrative global licensing deal. The dual listing on the Hong Kong Stock Exchange (HKEX) successfully closes, unlocking significant Asian capital and driving valuation multiples closer to mid-cap biotech peers.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Compelling clinical data for lead asset Givastomig, showing a 75%-77% ORR and 16.9-month mPFS in Phase 1b, outperforming standard of care.
Strong balance sheet with $210.8 million in cash and short-term investments, providing a clear runway through 2028.
Strategic backing from the CBC Group and a highly experienced management team, including the recent appointment of Mark Hagler as President and CCO.
FDA Fast Track Designation for Givastomig in first-line HER2-negative metastatic gastric cancer, accelerating the regulatory pathway.

Key Investment Risks

Clinical development risk inherent to mid-to-late-stage oncology and ophthalmology trials.
High cash burn rate driven by dual late-stage clinical programs (Givastomig Phase 3 and VIS-101 Phase 2b).
Material weaknesses in internal controls over financial reporting (specifically IT general controls) previously disclosed in SEC filings.

Thesis Invalidation Triggers

Failure to initiate the registrational Phase 3 trial for Givastomig by mid-2027.
A significant drop in the objective response rate (ORR) or unexpected safety issues in upcoming Givastomig clinical readouts.
Inability to advance VIS-101 into Phase 2b or disappointing durability data compared to competitors like Vabysmo.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.